相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1888
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Metformin did not meet the prespecified efficacy threshold for preventing patient-reported COVID-19 symptoms at 6 months in the ACTIV-6 trial of nearly 3,000 outpatient adults. - Participants receiving metformin experienced a 50% relative reduction in clinician-diagnosed long COVID compared with placebo (0.56% vs. 1.17% at 180 days). - The trial enrolled participants between September 2023 and May 2024, with over 83% having prior immunity from vaccination or infection, making results relevant to the current pandemic phase. - These findings replicate earlier COVID-OUT trial results, strengthening the case for metformin as an inexpensive, globally available intervention to reduce long COVID risk.
- University of Minnesota researchers demonstrated that fecal microbiota transplantation (FMT) achieved 78% 30-day survival rates in critically ill patients with fulminant C. difficile infection who were deteriorating despite intensive antibiotic therapy. - The FDA's halt of OpenBiome shipments in late 2024 has created access barriers for pediatric and immunocompromised patients, as approved drugs Vowst and Rebyota are not indicated for these populations. - A case study of a 7-year-old patient highlights the complex insurance approval process for off-label use of approved C. diff drugs, with Vowst costing $19,680 for a 12-pill course. - The regulatory shift from enforcement discretion to approved drug pathways has reduced treatment accessibility for vulnerable patient populations while potentially improving safety standards.
- Multiple randomized clinical trials and electronic health record studies demonstrate that metformin significantly reduces the risk of developing Long COVID when taken during or shortly after acute SARS-CoV-2 infection. - Research published in Clinical Infectious Diseases shows that on average, one case of Long COVID is prevented for every 50 cases of acute SARS-CoV-2 treated with 14 days of metformin. - The University of Minnesota Medical School findings establish metformin as the first intervention proven effective across low, standard, and high-risk adult populations in preventing Long COVID. - Metformin demonstrated additional benefits including significantly decreasing SARS-CoV-2 viral load and preventing viral rebound compared to placebo.
- Immusoft successfully re-dosed a patient with ISP-001 after 18 months, marking a historic breakthrough in gene therapy's ability to safely administer multiple doses. - The engineered B cell approach avoids dangerous immune responses and toxic chemotherapy regimens associated with traditional viral gene therapies and stem cell approaches. - The first patient showed durable benefits beyond one year and continued positive outcomes including pharmacodynamic, functional, and quality-of-life improvements after re-dosing. - A second patient has also been treated with encouraging initial results, demonstrating the platform's potential to transform treatment for genetic diseases like MPS I.
- Immusoft's ISP-001, an autologous B cell therapy engineered to express iduronidase enzyme, shows positive safety and initial activity in first-in-human MPS I trial without requiring preconditioning or immunosuppression. - The groundbreaking approach uses B cells as "biofactories" for therapeutic protein delivery, potentially offering a durable and redosable treatment option for patients with the rare lysosomal storage disease MPS I. - Clinical trial data will be presented by Dr. Paul Orchard from the University of Minnesota at the upcoming ASGCT Annual Meeting in New Orleans on May 14, 2025.
- A national assessment finds that only 41.8% of hematology/oncology fellows receive specific training for community-based careers, despite 80-85% of cancer patients receiving treatment in community settings. - Survey results indicate high demand for enhanced community-based training experiences, with 83% of fellowship program directors supporting the inclusion of community practice rotations during training. - Research led by Dr. Shubham Agrawal highlights the need for specialized training pathways, particularly in areas such as clinical operations, healthcare administration, and community-based clinical trials.
- The GRADE study, a large clinical trial comparing four diabetes medications added to metformin, found that insulin glargine and liraglutide performed modestly better at maintaining target blood glucose levels over five years. - Participants taking liraglutide or insulin glargine achieved approximately six months more time with blood glucose levels in the target range compared to sitagliptin, which was the least effective treatment. - Despite improvements with all four drugs, nearly three-quarters of study participants were unable to maintain recommended blood glucose levels throughout the five-year follow-up period. - Liraglutide demonstrated additional cardiovascular benefits, showing lower risk of diabetes-related cardiovascular disease compared to other medications in the study.
- A University of Minnesota study found that hydroxychloroquine did not prevent COVID-19 infection in high-risk healthcare workers, with 5.9% of the hydroxychloroquine group and 7.9% of the placebo group developing the virus. - The NIH's ORCHID trial concluded that hydroxychloroquine provides no clinical benefit to hospitalized adults with COVID-19, with similar health status observed in both hydroxychloroquine and placebo groups after 14 days. - Both studies reported side effects, such as nausea and upset stomach, but no increased risk of serious cardiac complications from hydroxychloroquine compared to placebo. - These findings align with other trials, reinforcing that hydroxychloroquine is not an effective treatment for preventing or improving outcomes in COVID-19 patients.
